The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
MYGN Buyback image

Myriad Genetics, Inc. Buyback

OLI recorded this information on 11/19/2018

Company: Myriad Genetics, Inc.
Buyback: MYGN buyback
$Amount Authorized: $50,000,000
Buyback Details: Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase ("ASR") agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock. Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the company's board of directors.

Myriad Genetics is genetic testing and precision medicine company. Co. provides insights that help people take control of their health and enable healthcare providers to detect, treat, and prevent disease. Co. discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical personnel. Co.'s molecular diagnostic tests are designed to analyze genes and their expression levels to assess an individual's risk for developing disease, determine a patient's likelihood of responding to a particular drug, or assess a patient's risk of disease progression.

MYGN SEC Filing Email Alerts Service

Open the MYGN Page at The Online Investor »

MYGN — Key Stats (updated 17 hours, 21 minutes ago)
Company Name:  Myriad Genetics, Inc.
Stock buyback:  MYGN buyback
Website:  www.myriad.com
Sector:  Biotechnology
Number of ETFs Holding MYGN:  51
Total Market Value Held by ETFs:  $417.69M
Total Market Capitalization:  $1.67B
% of Market Cap. Held by ETFs:  24.98%
 

Open the MYGN Page at The Online Investor (in a new window) »
April 26, 2024  •  4:05 AM Eastern
MYGN — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree MYGN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Hold (2.36 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
MYGN Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

MYGN Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.